Neximmune Rg

Clinical‑stage biotech developing injectable, T‑cell immunotherapy platform (Artificial Immune Modulation). Candidate therapies: NEXI‑001 (allogeneic AML), NEXI‑002 (autologous MM), NEXI‑003 (HPV‑cancer) in Phase I/II in the U.S.

Headquarters: United States (USA)

Website: Visit Site 🔗
Type: Corporation

Company Profile

Sector: Manufacturing
Industry: Pharmaceutical Manufacturing

Employees: 6
HQ: Gaithersburg

Unlock the full potential.

Get access to Relative P/E Ratio Valuation Histogram.

Upgrade

Traded Instruments

+ Add Instrument 1

Symbol	Name	Type	Exchange	Currency	ISIN	Status	Actions
NEXI	Neximmune Rg Cap: 0.0B	EQUITY	NMS	USD	US65344D1090	Active	📈